覆膜支架与裸金属支架治疗主髂动脉闭塞性疾病的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入10项研究(2项随机对照试验、8项回顾性队列研究,共1676例样本),比较覆膜支架与裸金属支架治疗主髂动脉闭塞性疾病的效果。结果显示,覆膜支架在TASC D级病变的一期通畅率、靶病变血运重建、技术成功率和长期生存率方面优于裸金属支架,但在全部患者的一期通畅率、二期通畅率、ABI变化、保肢率和并发症方面无显著差异。
要点
- 覆膜支架较裸金属支架降低靶病变血运重建风险(RR 0.39,95%CI 0.27-0.56,p<0.001)。
- TASC D级病变患者使用覆膜支架的一期通畅率更优(RR 1.15,95%CI 1.04-1.27,p=0.007)。
- 覆膜支架在技术成功率和长期生存率上优于裸金属支架,但全因一期通畅率等无显著差异。
核心结论
- 与裸金属支架相比,覆膜支架用于主髂动脉闭塞性疾病在TASC D级病变的一期通畅率、靶病变血运重建、技术成功率和患者长期生存率方面更有利,这些结果为覆膜支架治疗主髂动脉闭塞性疾病的优势提供了证据。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase和Cochrane Library截至2023年8月,纳入10项研究(2项随机对照试验、8项回顾性队列研究),共1676例样本。
主要发现
- 与裸金属支架相比,覆膜支架用于TASC D级病变患者的一期通畅率更高(RR 1.15,95%CI 1.04-1.27,p=0.007)。
- 覆膜支架的靶病变血运重建风险低于裸金属支架(RR 0.39,95%CI 0.27-0.56,p<0.001)。
- 覆膜支架的技术成功率高于裸金属支架(RR 1.01,95%CI 1.00-1.02,p=0.010)。
- 覆膜支架的长期生存率高于裸金属支架(RR 1.06,95%CI 1.01-1.11,p=0.020)。
- 覆膜支架与裸金属支架在全部患者的一期通畅率、二期通畅率、ABI变化、保肢率和并发症方面无显著差异。
关键数值与推荐
- TASC D级病变一期通畅率:覆膜支架组RR 1.15(95%CI 1.04-1.27,p=0.007),优于裸金属支架组。
- 靶病变血运重建:覆膜支架组RR 0.39(95%CI 0.27-0.56,p<0.001),风险低于裸金属支架组。
- 技术成功:覆膜支架组RR 1.01(95%CI 1.00-1.02,p=0.010),高于裸金属支架组。
- 长期生存:覆膜支架组RR 1.06(95%CI 1.01-1.11,p=0.020),高于裸金属支架组。
临床怎么用
- 作者认为,这些结果提供了支持覆膜支架优于裸金属支架用于主髂动脉闭塞性疾病治疗的证据,并为临床治疗决策提供指导。
局限性
- 未来需要针对ABI的长期变化、不同钙化程度的一期通畅率、血管节段和TASC分型开展进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to assess the efficacy and safety outcome of covered stents (CSs), as compared with bare-metal stents (BMSs), for the treatment of patients with aortoiliac occlusive disease (AIOD). MATERIALS AND METHODS: A systematic literature search was conducted in PubMed, Embase, and Cochrane Library up to August 2023 to identify all studies comparing efficacy and safety outcomes of CSs versus BMSs for treating AIOD. Our outcome was primary patency, secondary patency, technical success, ankle-brachial index (ABI) variation, target lesion revascularization (TLR), limb salvage, complications, and long-term survival. Dichotomous outcomes were pooled as relative risks (RR) or hazard ratio with the 95% confidence interval (CI). Continuous outcomes were pooled as weighted mean differences and 95% CI. Model selection was based on the heterogeneity of the included studies. RESULTS: There were 10 studies (2 randomized controlled trials, 8 retrospective cohort studies), comprising 1676 sample size. Compared with BMSs, CSs use was associated with better primary patency of patients with a Trans-Atlantic Inter-Society Consensus II (TASC) D lesion (RR, 1.15, 95% CI, 1.04 to 1.27, p=0.007), TLR (RR, 0.39, 95% CI, 0.27 to 0.56, p<0.001), technical success (RR, 1.01, 95% CI, 1.00 to 1.02, p=0.010), and long-term survival (RR, 1.06, 95% CI, 1.01 to 1.11, p=0.020). There is no difference between CSs and BMSs regarding primary patency of all patients, secondary patency, variation in ABI, limb salvage, and complications. CONCLUSIONS: Compared with BMSs, CSs used in AIOD was associated with more favorable primary patency in patients with TASC D lesions, TLR, technical success rates, and patient long-term survival. These results provide evidence of the advantages of using CSs for AIOD treatment. Future studies focusing on long-term variations in ABI, primary patency of different degrees of calcification, vascular segments, and TASC classification are warranted.Clinical ImpactAlthough several studies evaluated the clinical efficacy of CS in the context of AIOD treatment, the significance and consistency of these findings were not determined to date. We found that CS was used in AIOD associated with better technical success rate, long-term patient survival, lower target lesion revascularization, and higher primary patency of patients with a Trans-Atlantic Inter-Society Consensus II D lesion when compared with BMSs. Our study provides evidence supporting the superiority of CSs over BMSs in the treatment of AIOD, and furnishing clinicians with guidance for treatment decisions.
引用
- Hu C, Chen L, Wu M, et al. Efficacy and Safety of Covered Stents Versus Bare-Metal Stents for Aortoiliac Occlusive Disease: A Systematic Review and Meta-Analysis. J Endovasc Ther. 2024. PMID: 38491926. doi:10.1177/15266028241237387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。